176 related articles for article (PubMed ID: 37773118)
21. Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.
Dass SA; Tan KL; Selva Rajan R; Mokhtar NF; Mohd Adzmi ER; Wan Abdul Rahman WF; Tengku Din TADA; Balakrishnan V
Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33445543
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
23. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
24. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
25. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
[TBL] [Abstract][Full Text] [Related]
26. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
27. Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers.
Abd El-Hafez A; Shawky Mohamed Ael-A; Elesawy BH
Asian Pac J Cancer Prev; 2013; 14(2):1037-41. PubMed ID: 23621182
[TBL] [Abstract][Full Text] [Related]
28. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of male triple negative breast cancer: A population-based study.
Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
[TBL] [Abstract][Full Text] [Related]
31. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
[TBL] [Abstract][Full Text] [Related]
32. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
33. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.
Li Y; Kong X; Wang Z; Xuan L
J Cell Mol Med; 2022 Mar; 26(5):1351-1362. PubMed ID: 35150062
[TBL] [Abstract][Full Text] [Related]
34. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.
Sharma M; Sharma JD; Sarma A; Ahmed S; Kataki AC; Saxena R; Sharma D
Asian Pac J Cancer Prev; 2014; 15(11):4507-11. PubMed ID: 24969877
[TBL] [Abstract][Full Text] [Related]
35. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
36. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
[TBL] [Abstract][Full Text] [Related]
37. Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer.
Kim H; Lee H; Choi DH; Park W; Cho WK; Nam SJ; Lee JE; Kim SW; Lee SK; Cho EY; Cho SY
Asia Pac J Clin Oncol; 2022 Feb; 18(1):28-34. PubMed ID: 33058534
[TBL] [Abstract][Full Text] [Related]
38. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of comprehensive typing based on m6A and gene cluster in TNBC.
Wu H; Feng J; Wu J; Zhong W; Zouxu X; Huang W; Huang X; Yi J; Wang X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4367-4380. PubMed ID: 36109402
[TBL] [Abstract][Full Text] [Related]
40. Recent treatment progress of triple negative breast cancer.
Chang-Qing Y; Jie L; Shi-Qi Z; Kun Z; Zi-Qian G; Ran X; Hui-Meng L; Ren-Bin Z; Gang Z; Da-Chuan Y; Chen-Yan Z
Prog Biophys Mol Biol; 2020 Mar; 151():40-53. PubMed ID: 31761352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]